CINECA IRIS Institutional Research Information System

DI PAOLO, ANTONELLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.700
AS - Asia 7.875
EU - Europa 6.043
SA - Sud America 1.301
Continente sconosciuto - Info sul continente non disponibili 539
AF - Africa 378
OC - Oceania 32
Totale 35.868
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.140
SG - Singapore 2.418
CN - Cina 2.119
IT - Italia 2.058
HK - Hong Kong 1.227
BR - Brasile 1.078
SE - Svezia 979
VN - Vietnam 632
DE - Germania 532
BG - Bulgaria 484
FR - Francia 399
GB - Regno Unito 391
CA - Canada 386
TR - Turchia 315
FI - Finlandia 278
RU - Federazione Russa 236
IN - India 220
JP - Giappone 193
UA - Ucraina 161
KR - Corea 155
CI - Costa d'Avorio 101
BD - Bangladesh 99
NL - Olanda 80
CH - Svizzera 78
BE - Belgio 74
MX - Messico 73
IQ - Iraq 70
ZA - Sudafrica 66
AR - Argentina 65
SA - Arabia Saudita 53
PL - Polonia 52
UZ - Uzbekistan 51
ES - Italia 47
PK - Pakistan 46
ID - Indonesia 44
GR - Grecia 42
NG - Nigeria 39
CO - Colombia 38
EG - Egitto 34
AT - Austria 31
EC - Ecuador 29
AU - Australia 27
MA - Marocco 27
IE - Irlanda 25
IR - Iran 23
SN - Senegal 23
AE - Emirati Arabi Uniti 22
PH - Filippine 22
VE - Venezuela 21
CL - Cile 20
DK - Danimarca 20
PY - Paraguay 20
TT - Trinidad e Tobago 20
KE - Kenya 19
MY - Malesia 19
JO - Giordania 18
CR - Costa Rica 17
TN - Tunisia 17
DZ - Algeria 16
TH - Thailandia 15
OM - Oman 13
CZ - Repubblica Ceca 12
LT - Lituania 12
TW - Taiwan 12
NP - Nepal 11
PE - Perù 11
BO - Bolivia 10
JM - Giamaica 10
KZ - Kazakistan 9
NI - Nicaragua 9
LB - Libano 8
RS - Serbia 8
AZ - Azerbaigian 7
DO - Repubblica Dominicana 7
IL - Israele 7
PS - Palestinian Territory 7
UY - Uruguay 7
BB - Barbados 6
HU - Ungheria 6
KW - Kuwait 6
RO - Romania 6
BY - Bielorussia 5
ET - Etiopia 5
HN - Honduras 5
KG - Kirghizistan 5
NO - Norvegia 5
PA - Panama 5
AM - Armenia 4
BF - Burkina Faso 4
BJ - Benin 4
GT - Guatemala 4
MN - Mongolia 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
SV - El Salvador 4
BH - Bahrain 3
BZ - Belize 3
CG - Congo 3
HR - Croazia 3
KH - Cambogia 3
Totale 35.265
Salva come PNG Salva come JPEG
Città #
Ashburn 1.937
Woodbridge 1.783
Houston 1.616
Ann Arbor 1.492
Fairfield 1.433
Singapore 1.381
Hong Kong 1.206
Santa Clara 854
Dallas 835
San Jose 789
Chandler 788
Seattle 628
Wilmington 504
Cambridge 492
Shanghai 490
Sofia 479
Milan 440
Beijing 433
Council Bluffs 372
New York 364
Serra 294
Boardman 259
Ottawa 256
Los Angeles 243
Princeton 231
Lawrence 192
Hefei 179
Lauterbourg 178
Jacksonville 174
Medford 174
Izmir 159
Tokyo 159
Ho Chi Minh City 137
Nanjing 137
Seoul 135
Dearborn 130
Hanoi 121
Des Moines 118
Munich 107
Dong Ket 103
Abidjan 101
London 99
São Paulo 95
Florence 94
Istanbul 93
Pisa 91
Buffalo 90
Washington 84
Helsinki 83
San Diego 83
Redondo Beach 80
Frankfurt am Main 78
Rome 72
The Dalles 72
Chicago 70
Brussels 68
Columbus 68
Redwood City 60
Boulder 58
Nanchang 58
Kunming 49
Bern 48
Ogden 45
Rio de Janeiro 44
Toronto 44
Tashkent 42
Turku 42
Atlanta 39
Falls Church 38
Lagos 38
Belo Horizonte 36
Shenyang 35
Norwalk 34
Pune 34
Changsha 33
Warsaw 33
Bremen 32
Phoenix 32
Hebei 29
Montreal 27
Zurich 27
Orem 26
Baghdad 24
Jiaxing 24
Lucca 24
Dakar 23
Ankara 22
Brooklyn 22
Dhaka 22
San Francisco 22
Denver 21
Düsseldorf 21
Guangzhou 21
Curitiba 20
Johannesburg 20
Jüchen 20
Riyadh 20
Cape Town 19
Jakarta 19
Nuremberg 19
Totale 24.589
Salva come PNG Salva come JPEG
Nome #
DECONTAMINAZIONE CON GENTAMICINA ORALE NEI PAZIENTI CON COLONIZZAZIONE INTESTINALE DA KLEBSIELLA PNEUMONIAE PRODUTTRICE DI KPC IN CORSO DI EPIDEMIA 539
A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity 357
Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 300
Procedimento attuato per mezzo di un elaboratore per la determinazione dei tempi di ritenzione e dei valori di concentrazione di analiti in una miscela 288
Determination of mitotane and principal metabolite by a simple HPLC-UV method and its validation in human plasma sample 287
Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers 279
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib 279
A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma 277
A new validated HPLC-UV method for therapeutic monitoring of daptomycin in comparison with reference LC-MS/MS 271
Gender, MGMT methylation, and levetiracetam plasma levels correlate with survival benefit in glioblastoma patients treated with adjuvant temozolomide: results from a non-interventional retrospective clinical study 262
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis 258
Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections 256
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 254
Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study 254
Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review—Part I 249
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 247
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 245
Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: implications for drug monitoring in children with acute lymphoblastic leukemia 242
Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteers 239
ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. 238
A new validated HPLC-UV method for therapeutic monitoring of daptomycin in comparison with reference Mass Spectrometry 233
IN THE CHRONIC MYELOID LEUKEMIA THE SALIVARY PROTEOMICS RECAPITULATES SOME ASPECTS OF THE LEUKEMIC STEM CELL. LA CELLULA STAMINALE LEUCEMICA E LA PROTEOMICA SALIVARE: IL MODELLO DELLA LEUCEMIA MIELOIDE CRONICA 232
ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients 227
Determination of mitotane and metabolite by a simple HPLC-UV method and application in plasma samples 223
Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients 221
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 219
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 218
Autoimmune diseases and myeloid hematological disorders: a possible pathogenetic relationship 215
Personalized medicine of monoclonal antibodies in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and beyond 214
Fungicidal activity and PK/PD of caspofungin as tools to guide antifungal therapy in a fluconazole-resistant C. parapsilosis candidemia 212
The role of thymidylate synthase as a molecular biomarker 211
Pharmacogenetics in Oncology 211
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity 209
Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily 208
5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer 208
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 207
Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib 205
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. 204
Combined unfavourable polymorphisms ofhOCT1 and ABCG2 are responsible for delayed complete cytogenetic response during imatinib treatment. 204
Linezolid in the central nervous system: Comparison between cerebrospinal fluid and plasma pharmacokinetics 201
An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients 201
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 199
A case report of a TDM-guided optimization of mitotane for a safe and effective long-term treatment 199
Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients 198
Therapeutic monitoring of Piperacillin in ICU patients 197
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia 197
Impact of locoregional approaches to liver metastases in patients with colorectal cancer 196
5-Fluorouracil exposure in adjuvant chemotherapy regimens is significantly related to disease free survival in colorectal cancer patients 196
Methods: For studying pharmacogenetic profiles of combination chemotherapeutic drugs 195
Daptomycin Population Pharmacokinetics in Patients Affected by Severe Gram-Positive Infections: An Update 194
Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges 194
Chronic administration of suramin induces neurotoxicity in rats 193
Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteers 192
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 191
Appropriateness of repetitive therapeutic drug monitoring and laboratory turn around time 191
Transmembrane Transporters hOCT1 and SLCO1B3 Polymorphisms Could Have a Role in Patients Affected By Chronic Myeloid Leukemia Treated with Nilotinib 190
A new HPLC-UV method compared with HPLC-MS for daptomycin levels in human plasma samples 190
Serotonin syndrome and the T102-->C polymorphism of the 5-HT2A receptor: a case report 189
Case report of a successful treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and MRSA/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin 189
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 188
Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis 188
Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells 187
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer 187
ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview 187
Time-dependent Pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer 186
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 186
An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma. 186
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 186
Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis 186
A PRACTICAL APPROACH TO THERAPEUTIC DRUG MONITORING OF IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID ELEUKEMIA. THE TIKLET PROTOCOL. 185
Genetic polymorphisms of thiopurine S-methyltransferase in a cohort of patients with systemic autoimmune diseases 185
Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role 184
Genotype A1/A2 associated with neuroleptic malignant syndrome 184
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma 183
Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate 183
The pharmacological bases of the antiangiogenic activity of paclitaxel 182
Precision medicine in lymphoma by innovative instrumental platforms 180
Predicting survival with artificial neural networks 179
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction 179
Clinical Pharmacokinetics of Antibacterials in Cerebrospinal Fluid 179
Different recommendations for daptomycin dosing over time in patients with severe infections 179
Irinotecan in 5-fluorouracil-refractory colorectal cancer 177
Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. 174
Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer 173
Inhibitory effect of the somatostatin analogue SMS 201-995 and cytokines on the proliferation of human colon adenocarcinoma cell lines 172
Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: A preclinical study 172
Liposomal anticancer therapy: pharmacokinetic and clinical aspects 170
Linezolid for endocarditis: a case series of 14 patients 170
Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: the relevance of concomitant systemic antibiotic therapy. 170
Pharmacogenetic determinants of anti-cancer drug activity and toxicity 170
Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. 169
Administration interval and daptomycin toxicity: a case report of rhabdomyolysis 167
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. 167
Combined FAMD and ANOVA investigation leads to significant association between the hOCT1/ABCB1 diplotype and both efficacy and tolerability in patients affected by chronic myeloid leukemia 165
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 165
Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling 164
Pharmacogenetics of Antiangiogenic Therapy 162
Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer 162
Pharmacogenetics of BCR/ABL inhibitors in chronic myeloid leukemia 162
Cardiovascular implantable electronic device endocarditis treated with daptomycin with or without transvenous removal 161
Totale 20.835
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.452
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.452
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.292 0 134 90 128 378 385 86 125 93 95 131 647
2022/20232.747 390 318 181 232 301 410 39 210 453 22 168 23
2023/20242.101 229 237 253 123 269 371 95 104 51 50 87 232
2024/20257.093 41 243 78 344 700 694 595 403 662 842 720 1.771
2025/20267.344 465 931 887 722 740 667 1.059 388 481 610 235 159
2026/20271.680 596 1.084 0 0 0 0 0 0 0 0 0 0
Totale 35.868